Impact of offsetting midyear list price and rebate reductions in Medicare Part D

  • Print
  • Connect
  • Email
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
By David R. Mike, Matthew Hayes | 05 April 2019
The structure of the Medicare Part D program produces interesting, and sometimes counterintuitive, financial outcomes when drug list prices are decreased and rebates are eliminated. This paper analyzes the impact of mid-year drug list price reductions coupled with a reduction in rebates resulting in identical net price.